JP2012505896A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505896A5 JP2012505896A5 JP2011532190A JP2011532190A JP2012505896A5 JP 2012505896 A5 JP2012505896 A5 JP 2012505896A5 JP 2011532190 A JP2011532190 A JP 2011532190A JP 2011532190 A JP2011532190 A JP 2011532190A JP 2012505896 A5 JP2012505896 A5 JP 2012505896A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkenyl
- compound according
- compound
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 168
- 125000000217 alkyl group Chemical group 0.000 claims 130
- 125000003342 alkenyl group Chemical group 0.000 claims 85
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 58
- 125000000623 heterocyclic group Chemical group 0.000 claims 33
- 125000005842 heteroatom Chemical group 0.000 claims 19
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 18
- 229910052760 oxygen Inorganic materials 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims 13
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 12
- 208000017169 kidney disease Diseases 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 239000000126 substance Substances 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 201000001320 Atherosclerosis Diseases 0.000 claims 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims 6
- 206010048768 Dermatosis Diseases 0.000 claims 6
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 6
- 208000032928 Dyslipidaemia Diseases 0.000 claims 6
- 208000002705 Glucose Intolerance Diseases 0.000 claims 6
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 6
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 6
- 206010020772 Hypertension Diseases 0.000 claims 6
- 208000013016 Hypoglycemia Diseases 0.000 claims 6
- 206010022489 Insulin Resistance Diseases 0.000 claims 6
- 206010023379 Ketoacidosis Diseases 0.000 claims 6
- 208000007976 Ketosis Diseases 0.000 claims 6
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 6
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 208000008589 Obesity Diseases 0.000 claims 6
- 206010030113 Oedema Diseases 0.000 claims 6
- 201000001880 Sexual dysfunction Diseases 0.000 claims 6
- 208000007536 Thrombosis Diseases 0.000 claims 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 208000033679 diabetic kidney disease Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 201000006549 dyspepsia Diseases 0.000 claims 6
- 201000001421 hyperglycemia Diseases 0.000 claims 6
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 6
- 201000008980 hyperinsulinism Diseases 0.000 claims 6
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims 6
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 6
- 230000002218 hypoglycaemic effect Effects 0.000 claims 6
- 235000020824 obesity Nutrition 0.000 claims 6
- 201000009104 prediabetes syndrome Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 231100000872 sexual dysfunction Toxicity 0.000 claims 6
- 208000017520 skin disease Diseases 0.000 claims 6
- 208000011580 syndromic disease Diseases 0.000 claims 6
- -1 wherein Chemical group 0.000 claims 6
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 claims 3
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 2
- 229940123464 Thiazolidinedione Drugs 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000000455 heteroaryl-fused-cycloalkyl group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 2
- 229960003105 metformin Drugs 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- 241000257303 Hymenoptera Species 0.000 claims 1
- 125000005137 alkenylsulfonyl group Chemical group 0.000 claims 1
- 125000004948 alkyl aryl alkyl group Chemical group 0.000 claims 1
- 125000001374 aryl-fused-cycloalkyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 0 CC1C(C)(C)*CC1 Chemical compound CC1C(C)(C)*CC1 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19627108P | 2008-10-15 | 2008-10-15 | |
| US61/196,271 | 2008-10-15 | ||
| PCT/US2009/060549 WO2010045258A2 (en) | 2008-10-15 | 2009-10-13 | Spirocyclic gpr40 modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012505896A JP2012505896A (ja) | 2012-03-08 |
| JP2012505896A5 true JP2012505896A5 (cg-RX-API-DMAC7.html) | 2012-11-22 |
| JP5551707B2 JP5551707B2 (ja) | 2014-07-16 |
Family
ID=41835743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011532190A Expired - Fee Related JP5551707B2 (ja) | 2008-10-15 | 2009-10-13 | スピロ環ｇｐｒ４０調節因子 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8748462B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2358656B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5551707B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009303475B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2739888C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2450567T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011003917A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010045258A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2813639A1 (en) | 2010-10-08 | 2012-04-12 | Mochida Pharmaceutical Co. Ltd. | Cyclic amide derivative |
| JP5853317B2 (ja) * | 2010-12-01 | 2016-02-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | インダニルオキシジヒドロベンゾフラニル酢酸 |
| CA2834417A1 (en) | 2011-04-27 | 2012-11-01 | Mochida Pharmaceutical Co., Ltd. | Novel 3-hydroxyisothiazole 1-oxide derivative |
| JPWO2012147516A1 (ja) | 2011-04-28 | 2014-07-28 | 持田製薬株式会社 | 環状アミド誘導体 |
| CN103930418A (zh) * | 2011-06-23 | 2014-07-16 | 威尔金制药有限公司 | 金属酶抑制剂化合物 |
| KR20140138243A (ko) | 2012-02-28 | 2014-12-03 | 피라말 엔터프라이지즈 리미티드 | G 단백질 연결 수용체 작용물질로서의 페닐알칸산 유도체 |
| US8642585B2 (en) * | 2012-03-26 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
| US8809376B2 (en) | 2012-04-30 | 2014-08-19 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
| MA37649B1 (fr) * | 2012-05-17 | 2017-03-31 | Array Biopharma Inc | Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées |
| JP2015522080A (ja) | 2012-07-11 | 2015-08-03 | エルセリクス セラピューティクス インコーポレイテッド | スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物 |
| RU2015106909A (ru) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | Антидиабетические трициклические соединения |
| WO2014086712A1 (en) | 2012-12-07 | 2014-06-12 | Boehringer Ingelheim International Gmbh | New indanyloxydihydrobenzofuranylacetic acids |
| KR20150118158A (ko) | 2013-02-22 | 2015-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 비시클릭 화합물 |
| AR096041A1 (es) | 2013-04-17 | 2015-12-02 | Piramal Entpr Ltd | Derivados de ácido carboxílico alquilo sustituidos como agonistas rpg |
| JP5975081B2 (ja) | 2013-09-30 | 2016-08-23 | ダイキン工業株式会社 | 含フッ素ビアリール化合物の製造方法 |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| JP6352415B2 (ja) | 2013-11-14 | 2018-07-04 | カディラ・ヘルスケア・リミテッド | 新規なヘテロ環化合物 |
| ES2747973T3 (es) | 2013-11-15 | 2020-03-12 | Merck Sharp & Dohme | Compuestos tricíclicos antidiabéticos |
| EP3076959B1 (en) | 2013-12-04 | 2018-07-04 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2015089809A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
| WO2015119899A1 (en) | 2014-02-06 | 2015-08-13 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| CN105001212B (zh) * | 2014-04-16 | 2018-01-16 | 江苏柯菲平医药股份有限公司 | 稠环化合物及其制备方法和应用 |
| WO2015176267A1 (en) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US10968193B2 (en) | 2014-08-08 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US10100042B2 (en) | 2014-08-08 | 2018-10-16 | Merck Sharp & Dohme Corp. | [5,6]—fused bicyclic antidiabetic compounds |
| WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
| WO2016022448A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| EP3436003B1 (en) | 2016-03-29 | 2023-08-23 | Merck Sharp & Dohme LLC | Antidiabetic bicyclic compounds |
| WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| US10913720B2 (en) | 2017-01-26 | 2021-02-09 | Boehringer Ingelheim International Gmbh | Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| US10603317B2 (en) | 2017-01-26 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| JP7049349B2 (ja) | 2017-01-26 | 2022-04-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 |
| WO2018138027A1 (en) | 2017-01-26 | 2018-08-02 | Boehringer Ingelheim International Gmbh | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceuticalcompositions and uses thereof |
| US10550127B1 (en) | 2017-02-08 | 2020-02-04 | Boehringer Ingelheim International Gmbh | Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes |
| AR111199A1 (es) | 2017-03-31 | 2019-06-12 | Takeda Pharmaceuticals Co | Compuesto aromático agonista de gpr40 |
| US11225471B2 (en) | 2017-11-16 | 2022-01-18 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| EP3762379A1 (en) | 2018-03-07 | 2021-01-13 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
| CA3093130C (en) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| TWI809427B (zh) | 2018-07-13 | 2023-07-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| EP3870566A1 (en) | 2018-10-24 | 2021-09-01 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN112010881B (zh) * | 2019-05-30 | 2021-09-03 | 中国科学院兰州化学物理研究所 | 一种烯基硼化合物及其制备方法与应用 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE305216B (cg-RX-API-DMAC7.html) | 1965-09-17 | 1968-10-21 | Astra Apotekarnes Kem Fab | |
| FR2359135A1 (fr) | 1976-07-22 | 1978-02-17 | Hexachimie | Nouvelles phenoxyhydroxypropylamines, procede pour les preparer et leur application en therapeutique |
| US4760089A (en) | 1985-09-09 | 1988-07-26 | Smithkline Beckman Corporation | Irreversible dopamine-β-hydroxylase inhibitors |
| PT85081A (en) | 1986-06-19 | 1987-07-01 | Smithkline Beckman Corp | Irreversible dopamine-beta-hydroxylase inhibitors |
| GB8917069D0 (en) | 1989-07-26 | 1989-09-13 | Merck Sharp & Dohme | Therapeutic agents |
| DE4019307A1 (de) | 1990-06-16 | 1991-12-19 | Bayer Ag | 2-methoximinocarbonsaeureester |
| US5536727A (en) | 1992-05-20 | 1996-07-16 | Merck & Co., Inc. | 17-Ethers and thioethers of 4-aza-steroids |
| WO1993023041A1 (en) | 1992-05-20 | 1993-11-25 | Merck & Co., Inc. | Ester derivatives of 4-aza-steroids |
| DE4241632A1 (de) | 1992-12-10 | 1994-06-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| IL110159A0 (en) | 1993-06-30 | 1994-10-07 | Wellcome Found | Diaryl compounds, their preparation and pharmaceutical compositions containing them |
| US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| WO1997003945A1 (en) | 1995-07-14 | 1997-02-06 | Smithkline Beecham Corporation | Substituted-pent-4-ynoic acids |
| US5795900A (en) | 1995-10-03 | 1998-08-18 | Abbott Laboratories | Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis |
| JPH10316641A (ja) | 1997-03-14 | 1998-12-02 | Sankyo Co Ltd | カルボン酸誘導体 |
| AU8750298A (en) | 1997-08-28 | 1999-03-22 | Ono Pharmaceutical Co. Ltd. | Peroxisome proliferator-activated receptor controllers |
| US6645939B1 (en) | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
| DE69941777D1 (de) | 1998-03-10 | 2010-01-21 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| DE19941567A1 (de) | 1998-09-05 | 2000-04-20 | Merck Patent Gmbh | Neue flüssigkristalline Verbindungen |
| AU3958200A (en) | 1999-04-20 | 2000-11-02 | Novo Nordisk A/S | New compounds, their preparation and use |
| AU4591800A (en) | 1999-05-05 | 2000-11-21 | Aventis Pharma Limited | Ureas as cell adhesion modulators |
| GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| GB9927056D0 (en) | 1999-11-17 | 2000-01-12 | Karobio Ab | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
| AU1624801A (en) | 1999-11-19 | 2001-05-30 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists related applications |
| JP2001242165A (ja) | 2000-02-25 | 2001-09-07 | Dai Ichi Seiyaku Co Ltd | 採血用試薬 |
| JP2002003368A (ja) | 2000-06-23 | 2002-01-09 | Saitama Daiichi Seiyaku Kk | 経皮吸収又は経粘膜吸収用の製剤 |
| GB0031107D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| GB0031527D0 (en) | 2000-12-22 | 2001-02-07 | Smithkline Beecham Plc | New use |
| US6906046B2 (en) | 2000-12-22 | 2005-06-14 | Celltech R & D Inc. | Pharmaceutical uses and synthesis of benzobicyclooctanes |
| WO2002053547A1 (en) | 2000-12-28 | 2002-07-11 | Takeda Chemical Industries, Ltd. | Alkanoic acid derivatives, process for their production and use thereof |
| TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
| PL367077A1 (en) | 2001-06-07 | 2005-02-21 | Eli Lilly And Company | Modulators of peroxisome proliferator activated receptors (ppar) |
| US7345068B2 (en) | 2002-02-07 | 2008-03-18 | Hitoshi Endou | Aromatic amino acid derivatives and medicinal compositions |
| EP1479768B1 (en) | 2002-02-14 | 2010-04-28 | Takeda Pharmaceutical Company Limited | Novel screening method |
| US20030207924A1 (en) | 2002-03-07 | 2003-11-06 | Xue-Min Cheng | Compounds that modulate PPAR activity and methods of preparation |
| US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
| CA2487315A1 (en) | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
| GB0214149D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| US7553867B2 (en) | 2002-09-06 | 2009-06-30 | Takeda Pharmaceutical Company Limited | Furan or thiophene derivative and medicinal use thereof |
| CA2505322A1 (en) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | Receptor function regulator |
| US6906406B2 (en) * | 2002-12-19 | 2005-06-14 | Freescale Semiconductor, Inc. | Multiple dice package |
| US20060258683A1 (en) | 2003-04-07 | 2006-11-16 | Liu Kevin | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
| JP4805552B2 (ja) * | 2003-05-30 | 2011-11-02 | 武田薬品工業株式会社 | 縮合環化合物 |
| WO2004106276A1 (ja) | 2003-05-30 | 2004-12-09 | Takeda Pharmaceutical Company Limited | 縮合環化合物 |
| US7834013B2 (en) | 2003-11-19 | 2010-11-16 | Glaxosmithkline Llc | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40 |
| AU2004299456B2 (en) | 2003-12-17 | 2010-10-07 | Merck Sharp & Dohme Corp. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| BRPI0418148A (pt) | 2003-12-25 | 2007-04-17 | Takeda Pharmaceutical | composto, prodroga de um composto, modulador da função do receptor gpr40, agente farmacêutico, uso de um composto e métodos de modificação de uma função do receptor gpr40 em um mamìfero, de profilaxia ou tratamento de diabetes em um mamìfero e de produção de um composto |
| US7585880B2 (en) | 2003-12-26 | 2009-09-08 | Takeda Pharmaceutical Company Limited | Phenylpropanoic acid derivatives |
| WO2005080367A1 (en) | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
| US7816367B2 (en) | 2004-02-27 | 2010-10-19 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| CA2560111A1 (en) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
| EP1731505B1 (en) | 2004-03-30 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| JP2007269630A (ja) | 2004-06-23 | 2007-10-18 | Toudai Tlo Ltd | インスリン分泌促進剤 |
| US20060003344A1 (en) | 2004-06-30 | 2006-01-05 | Pfizer Inc. | Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40 |
| JP2007284350A (ja) | 2004-07-27 | 2007-11-01 | Takeda Chem Ind Ltd | 糖尿病治療剤 |
| JP2008528590A (ja) | 2005-01-28 | 2008-07-31 | メルク エンド カムパニー インコーポレーテッド | 抗糖尿病性二環式化合物 |
| ATE440091T1 (de) | 2005-01-31 | 2009-09-15 | Merck & Co Inc | Antidiabetische bicyclische verbindungen |
| US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| EP1916234B1 (en) | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| CA2621949A1 (en) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| WO2007049050A2 (en) | 2005-10-27 | 2007-05-03 | Heptahelix Ab | Modulators of gpr40 for the treatment of diabetes |
| AU2007225208A1 (en) * | 2006-03-14 | 2007-09-20 | Amgen Inc. | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders |
| TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
| DE102006021872B4 (de) | 2006-05-11 | 2008-04-17 | Sanofi-Aventis | 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102006021878A1 (de) | 2006-05-11 | 2007-11-15 | Sanofi-Aventis | Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102006021874B4 (de) | 2006-05-11 | 2008-03-27 | Sanofi-Aventis | 4,5-Diphenyl-pyrimidinyl-amino substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| PE20080069A1 (es) * | 2006-05-15 | 2008-02-22 | Merck & Co Inc | Compuestos biciclicos como agonistas del receptor 40 acoplado a proteina g (gpr40) |
| RS52307B (sr) | 2006-06-27 | 2012-12-31 | Takeda Pharmaceutical Company Limited | Kondenzovana ciklična jedinjenja |
| WO2008030618A1 (en) | 2006-09-07 | 2008-03-13 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
| CA2662305C (en) | 2006-09-07 | 2012-04-17 | Amgen Inc. | Heterocyclic gpr40 modulators |
| EP2079467B1 (en) | 2006-10-31 | 2015-11-18 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| EP2139843B1 (en) | 2007-04-16 | 2013-12-25 | Amgen, Inc | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators |
| JP5591706B2 (ja) | 2007-10-10 | 2014-09-17 | アムジエン・インコーポレーテツド | 置換ビフェニルｇｐｒ４０調節因子 |
-
2009
- 2009-10-13 WO PCT/US2009/060549 patent/WO2010045258A2/en not_active Ceased
- 2009-10-13 ES ES09741123.5T patent/ES2450567T3/es active Active
- 2009-10-13 MX MX2011003917A patent/MX2011003917A/es active IP Right Grant
- 2009-10-13 AU AU2009303475A patent/AU2009303475B2/en not_active Ceased
- 2009-10-13 JP JP2011532190A patent/JP5551707B2/ja not_active Expired - Fee Related
- 2009-10-13 CA CA2739888A patent/CA2739888C/en not_active Expired - Fee Related
- 2009-10-13 EP EP09741123.5A patent/EP2358656B1/en active Active
- 2009-10-13 US US13/119,951 patent/US8748462B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012505896A5 (cg-RX-API-DMAC7.html) | ||
| JP2011500562A5 (cg-RX-API-DMAC7.html) | ||
| CN111848614B (zh) | 吡啶酮衍生物及抗流感病毒药物组合物 | |
| Darwish et al. | Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists | |
| CN1069901C (zh) | N－苄基二氧代噻唑烷基苯甲酰胺衍生物及其制造方法 | |
| CA2739888C (en) | Spirocyclic gpr40 modulators | |
| CA2662305A1 (en) | Heterocyclic gpr40 modulators | |
| JP2009530281A5 (cg-RX-API-DMAC7.html) | ||
| JP2007500720A5 (cg-RX-API-DMAC7.html) | ||
| JP2019069940A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| Zhu et al. | N 2-Selective iodofunctionalization of olefins with NH-1, 2, 3-triazoles to provide N 2-alkyl-substituted 1, 2, 3-triazoles | |
| WO2007126043A1 (ja) | チアゾール環を含むカルボン酸誘導体の医薬用途 | |
| JP2009525275A (ja) | 多環式１，２，３，４−テトラヒドロ−イソキノリン誘導体およびｐｐａｒモジュレーターとしてのそれらを含む組成物 | |
| TW201427959A (zh) | 新穎化合物 | |
| KR20100098534A (ko) | 바이러스 폴리머라제 억제제 | |
| JP2017537111A (ja) | ヘテロ環式誘導体およびその使用 | |
| JP2018528159A (ja) | 芳香族スルホンアミド誘導体 | |
| AU2008263166A1 (en) | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | |
| CN1150185C (zh) | 被杂环化合物取代的丙醇胺衍生物、其制备方法、含有所述化合物的药物组合物及其用途 | |
| JP2005532392A5 (cg-RX-API-DMAC7.html) | ||
| JPH0912575A (ja) | ベンゾオキサジンおよびベンゾチアジン誘導体 | |
| CN109996797A (zh) | 作为乳酸脱氢酶的抑制剂的1h-吡唑-1-基-噻唑及其使用方法 | |
| AU2023377707A1 (en) | Glucagon-like peptide 1 receptor agonists | |
| Kallemeyn et al. | Development of a large-scale route to glecaprevir: Synthesis of the macrocycle via intramolecular etherification | |
| CN107162921B (zh) | 一类苯氧乙酸衍生物、其制备方法及其作为药物的用途 |